Repligen
RGEN
Repligen (RGEN) - Net assets
Net assets on the balance sheet as of March 2024 : $1.97 B
According to Repligen
's latest financial reports the company has $1.97 B in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
Repligen - Net assets on balance sheet (from 2001 to 2024)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2023-12-31 | $1.97 B | 3.17% |
| 2022-12-31 | $1.91 B | 9.18% |
| 2021-12-31 | $1.75 B | 14.45% |
| 2020-12-31 | $1.52 B | 44.29% |
| 2019-12-31 | $1.05 B | 72.16% |
| 2018-12-31 | $0.61 B | 4.06% |
| 2017-12-31 | $0.59 B | 250.52% |
| 2016-12-31 | $0.16 B | 37.49% |
| 2015-12-31 | $0.12 B | 9.86% |
| 2014-12-31 | $0.11 B | 7.55% |
| 2013-12-31 | $0.10 B | 23.49% |
| 2012-12-31 | $84.12 M | |
| 2011-03-31 | $67.08 M | 1.46% |
| 2010-03-31 | $66.12 M | -4.34% |
| 2009-03-31 | $69.12 M | 7.83% |
| 2008-03-31 | $64.1 M | 151.02% |
| 2007-03-31 | $25.53 M | 0.41% |
| 2006-03-31 | $25.43 M | 4.71% |
| 2005-03-31 | $24.28 M | -10.58% |
| 2004-03-31 | $27.16 M | 10.65% |
| 2003-03-31 | $24.54 M | -7.17% |
| 2002-03-31 | $26.44 M | -14.39% |
| 2001-03-31 | $30.89 M |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $89.28 B | 4,431.01% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | $46.84 B | 2,277.04% | 🇺🇸 USA |
 General Electric GE | $31.10 B | 1,478.35% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $16.54 B | 739.74% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | $82.88 M | -95.79% | 🇺🇸 USA |
 Novavax NVAX | -$0.72 B | -136.38% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | $2.38 B | 21.08% | 🇺🇸 USA |
 Bio-Techne TECH | $1.96 B | -0.36% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | $5.07 B | 157.48% | 🇺🇸 USA |
 Charles River Laboratories
CRL | $3.65 B | 85.68% | 🇺🇸 USA |